European Meeting on HIV & Hepatitis 2023

HIV-1 Integrase Resistance Associated Mutations and the Use of Dolutegravir in Sub- Saharan Africa: A Systematic Review and Meta-Analysis

European Meeting on HIV & Hepatitis 2022

HIV transmission clusters in Europe: A perspective view of Late presenters and Non-Late presenters

European Meeting on HIV & Hepatitis 2022

Characterization of SARS-CoV-2 epidemic and transmission dynamics in children over the four COVID-19 waves

European Meeting on HIV & Hepatitis 2022

Circulation of sars-cov-2 variants in central Italy: spike variability characterization by deep-sequencing

European Meeting on HIV & Hepatitis 2022

SARS-CoV-2 mutations and variants may muddle the sensitivity of COVID-19 diagnostic assays

European Meeting on HIV & Hepatitis 2022

Impact of SARS-CoV-2 omicron and delta sub-lineage AY.4.2 variant on neutralization by sera of patients treated with different licensed monoclonal antibodies

European Meeting on HIV & Hepatitis 2022

Levels and durability of humoral and T-specific responses after the booster dose of mRNA BNT162b2 vaccine in residents of a Long Term Care Facility

European Meeting on HIV & Hepatitis 2022

Transmitted drug resistance to integrase based first-line treatment in Europe, 2018-2021

European Meeting on HIV & Hepatitis 2022

HIV-1 Transmitted drug resistance and transmission clusters in newly diagnosed patients in Portugal between 2014 and 2019

European Meeting on HIV & Hepatitis 2022

Reaching the 95-95-95 targets will not eliminate HIV transmission in 2030 among individuals born in sub-Saharan Africa residing in the Netherlands

European Meeting on HIV & Hepatitis 2022

HIV reservoir quantification by combining total HIV-1 DNA assay and intact proviral DNA assay (IPDA) in one triplex digital PCR reaction

European Meeting on HIV & Hepatitis 2022

Temporal trend of drug- resistance and APOBEC editing in PBMC genotypic resistance tests from HIV-1 infected virologically suppressed individuals

European Meeting on HIV & Hepatitis 2022

Comparison of Markers of Inflammation and Associated Baseline Variables in Virologically Suppressed Participants in the TANGO Study at Week 144

European Meeting on HIV & Hepatitis 2022

Predictors of integrase resistance in individuals who failed a regimen containing dolutegravir in French and Italian clinical settings

European Meeting on HIV & Hepatitis 2022

Analysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree model

European Meeting on HIV & Hepatitis 2022

Changes in the HIV-1 3'- polypurine tract in patients failing dolutegravir in Brazil

European Meeting on HIV & Hepatitis 2022

Using social media to improve follow-up and routine checks on newly diagnosed young people living with HIV and their adherence to Antiretroviral Therapy

European Meeting on HIV & Hepatitis 2022

Resistance analysis of pre- treatment NS3 and NS5A variants in HCV genotype 1a, 1b and 3a infected patients in Croatia

European Meeting on HIV & Hepatitis 2022

Evaluation of the virological efficacy of switching to dolutegravir-based tritherapy in patients followed under real-life conditions in Abidjan, Côte d'Ivoire

European Meeting on HIV & Hepatitis 2022

Major protease resistance in West African HIV-1 subtypes is associated with novel protease mutations and accelerated gag evolution during second-line ART

European Meeting on HIV & Hepatitis 2022

Interpretation of the T66I and G118R mutations in integrase in HIV-2

European Meeting on HIV & Hepatitis 2022

Virological characterization of treatment failures and retreatment outcomes in patients infected with “unusual” HCV genotype 1 subtypes

European Meeting on HIV & Hepatitis 2022

The acquisition of positively charged amino acids in HBsAg C- terminus impairs HBsAg secretion, affects its structural stability and is associated with HBV-induced liver cancer

European Meeting on HIV & Hepatitis 2022